Zobrazeno 1 - 10
of 683
pro vyhledávání: '"Helen E Heslop"'
Autor:
Malcolm K Brenner, Cliona M Rooney, Sandhya Sharma, Birju Mehta, Helen E Heslop, Michael Schmueck-Henneresse, Huimin Zhang, Mae Woods, Naren U Mehta, Tim Sauer, Kathan S Parikh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking
Externí odkaz:
https://doaj.org/article/985699a1af68414aa3156eae8ad99f66
Autor:
Pinar Ataca Atilla, Mary K McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Brian Wesley Simons, Alexandra McLean Stevens, Michele S Redell, Helen E Heslop, Erden Atilla
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background C-type lectin-like molecule 1 (CLL-1) is highly expressed in acute myeloid leukemia (AML) but is absent in primitive hematopoietic progenitors, making it an attractive target for a chimeric antigen receptor (CAR) T-cell therapy. Here, we o
Externí odkaz:
https://doaj.org/article/7a32e4bf724e46cfb4155f71a646cc64
Autor:
Pradip Bajgain, Roopa Mucharla, John Wilson, Dan Welch, Usanarat Anurathapan, Bitao Liang, Xiaohua Lu, Kyle Ripple, John M Centanni, Christine Hall, David Hsu, Larry A Couture, Shubhranshu Gupta, Adrian P Gee, Helen E Heslop, Ann M Leen, Cliona M Rooney, Juan F Vera
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Broader implementation of cell-based therapies has been hindered by the logistics associated with the expansion of clinically relevant cell numbers ex vivo. To overcome this limitation, Wilson Wolf Manufacturing developed the G-Rex, a cell culture fl
Externí odkaz:
https://doaj.org/article/d53190c4394a4fa6b235fead97660163
Autor:
Zakaria Grada, Meenakshi Hegde, Tiara Byrd, Donald R Shaffer, Alexia Ghazi, Vita S Brawley, Amanda Corder, Kurt Schönfeld, Joachim Koch, Gianpietro Dotti, Helen E Heslop, Stephen Gottschalk, Winfried S Wels, Matthew L Baker, Nabil Ahmed
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
Targeted T cells are emerging as effective non-toxic therapies for cancer. Multiple elements, however, contribute to the overall pathogenesis of cancer through both distinct and redundant mechanisms. Hence, targeting multiple cancer-specific markers
Externí odkaz:
https://doaj.org/article/f6109ef91e37425bafdfbf5c6c19c49f
Autor:
Vita S Salsman, Kevin K H Chow, Donald R Shaffer, Huseyin Kadikoy, Xiao-Nan Li, Claudia Gerken, Laszlo Perlaky, Leonid S Metelitsa, Xiuhua Gao, Meena Bhattacharjee, Karen Hirschi, Helen E Heslop, Stephen Gottschalk, Nabil Ahmed
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e20267 (2011)
Cancer cells can live and grow if they succeed in creating a favorable niche that often includes elements from the immune system. While T lymphocytes play an important role in the host response to tumor growth, the mechanism of their trafficking to t
Externí odkaz:
https://doaj.org/article/8934db56267140b5836fc475bb10fb93
Autor:
Spyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, Aster G. Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Kimberly Mooney, Natalia Lapteva, Bambi J. Grilley, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Todd N. Eagar, George Carrum, Kevin A. Grimes, Ann M. Leen, Premal Lulla
Publikováno v:
Haematologica, Vol 108, Iss 7 (2022)
Defects in T-cell immunity to SARS-CoV-2 have been linked to an increased risk of severe COVID-19 (even after vaccination), persistent viral shedding and the emergence of more virulent viral variants. To address this T-cell deficit, we sought to prep
Externí odkaz:
https://doaj.org/article/fe01c9fbf22e4de38523e9244e616c26
Autor:
Meenakshi Hegde, Sujith K. Joseph, Farzana Pashankar, Christopher DeRenzo, Khaled Sanber, Shoba Navai, Tiara T. Byrd, John Hicks, Mina L. Xu, Claudia Gerken, Mamta Kalra, Catherine Robertson, Huimin Zhang, Ankita Shree, Birju Mehta, Olga Dakhova, Vita S. Salsman, Bambi Grilley, Adrian Gee, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Winfried S. Wels, Stephen Gottschalk, Nabil Ahmed
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Recurrent metastatic rhabdomyosarcoma remains largely incurable. Here, the authors describe a child with metastatic rhabdomyosarcoma who has durable response to HER2-specific CAR T cells and shows endogenous immune reactivity.
Externí odkaz:
https://doaj.org/article/924e95c7aec9406f9a123abaaaf5e1e2
Autor:
Swati Naik, Caridad A. Martinez, Bilal Omer, Ghadir Sasa, Khaled Yassine, Carl E. Allen, Kala Kamdar, Robert Orth, Mengfen Wu, Kathryn Leung, Stephen Gottschalk, Malcolm K. Brenner, Helen E. Heslop, Robert A. Krance
Publikováno v:
Blood Advances, Vol 3, Iss 18, Pp 2689-2695 (2019)
Allogeneic hematopoietic stem cell transplant (HSCT) for relapsed pediatric non-Hodgkin lymphoma (NHL) is often reserved for patients with certain NHL subtypes or high-risk disease whereas the remainder receive autologous HSCT. Given the aggressive n
Externí odkaz:
https://doaj.org/article/020f250cd68a4b3d97fada29f7019d63
Autor:
Ifigeneia Tzannou, Ayumi Watanabe, Swati Naik, Rachel Daum, Manik Kuvalekar, Kathryn S. Leung, Caridad Martinez, Ghadir Sasa, Mengfen Wu, Adrian P. Gee, Robert A. Krance, Stephen Gottschalk, Helen E. Heslop, Bilal Omer
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2571-2580 (2019)
Abstract: Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), and standard antiviral therapies are associated with significant side effects and development
Externí odkaz:
https://doaj.org/article/c60a0ab90f4b4a43a83c0af8a30c6454
Autor:
Caridad Martinez, Paibel Aguayo-Hiraldo, Natalia Chaimowitz, Lisa Forbes, Nicholas Rider, Sarah Nicholas, Filiz Seeborg, Javier Chinen, Ivan Chinn, Carla Davis, Howard Roseblatt, Lenora Noroski, Bilal Omer, Tami John, Khaled Yassine, Swati Naik, John Craddock, Saleh Bhar, Carl Allen, Nabil Ahmed, Ghadir Sasa, David Steffin, Erin Doherty, Anil George, Baheyeldin Salem, Brian Friend, Meenakshi Hegde, Malcolm K. Brenner, Helen E. Heslop, Ann Leen, Amanda Peña, Mengfen Wu, I. Celine Hanson, Robert A. Krance
Publikováno v:
Blood Advances. 7:1823-1830
There is no consensus on the best donor for children with nonmalignant disorders and immune deficiencies in the absence of a matched related donor (MRD). We evaluated the 2-year overall survival (OS) after umbilical cord blood transplantation (UCBT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc7fc0256a98d4f2a03b2a78e82ab559
https://doi.org/10.1182/bloodadvances.2022009038
https://doi.org/10.1182/bloodadvances.2022009038